Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

96.250
-1.800-1.84%
Volume:8.90M
Turnover:843.31M
Market Cap:167.96B
PE:204.79
High:96.600
Open:94.200
Low:92.400
Close:98.050
52wk High:112.700
52wk Low:69.550
Shares:1.75B
HK Float Shares:1.75B
Volume Ratio:0.87
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.470
ROE:7.01%
ROA:2.23%
PB:6.92
PE(LYR):204.79
PS:9.14

Loading ...

Innovent Biologics - Lilly to Continue Manufacturing, Supply, and Development of Verzenios

THOMSON REUTERS
·
Jun 30

Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI

Dow Jones
·
Jun 29

Innovent Biologics' Diabetes Drug Passes Initial Review for Chinese Insurance List Inclusion

MT Newswires Live
·
Jun 29

Innovent Biologics' Mazdutide Passes Preliminary Review for China Medical Insurance Drug List- Official Statement

THOMSON REUTERS
·
Jun 29

Innovent Biologics Spokesperson: Only Treatment for Diabetes Can be Considered in Terms of Medical Insurance Coverage in China

THOMSON REUTERS
·
Jun 29

HK Movers | Hang Seng up More Than 2% Intraday, Led by CSPC PHARMA, INNOVENT BIO and Baidu

Tiger Newspress
·
Jun 29

Movement Alert|Innovent Biologics Rises 3.53% in Regular Trading, Partner Completes $330 Million Financing Amid Sector Rally

Market Focus
·
Jun 29

Movement Alert|Innovent Biologics Falls 3.01% in Regular Trading, Shareholder Meeting Resolutions Face High Opposition Amid Sector Weakness

Market Focus
·
Jun 25

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of Ibi324 (oln324) in Dme and Wet Amd; Studies Commencing in Second Half of 2026

THOMSON REUTERS
·
Jun 25

Innovent Biologics Files Directors List with Hong Kong Stock Exchange

Reuters
·
Jun 25

Ollin Raises $330 Million to Fund Late-stage Eye Disease Drug Trials

Reuters
·
Jun 24

Movement Alert|Innovent Biologics Rises 3.01% in Regular Trading, IBI3003 Phase III First Patient Dosing Continues to Drive Sentiment

Market Focus
·
Jun 24

JPMorgan Chase Increases Stake in Innovent Bio by Approximately 1.07 Million Shares at HK$75.40 Each

Stock News
·
Jun 23

Hong Kong Stocks Surge: Innovative Drug Sector Rallies on Regulatory Report and New Foreign Investment Policies

Stock News
·
Jun 23

Movement Alert|Innovent Biologics Rises 3.32% in Regular Trading, IBI3003 Phase III First Patient Dosing Combined with Biotech Sector Rebound

Market Focus
·
Jun 23

Movement Alert|Innovent Biologics Falls 3.68% in Regular Trading, Biotechnology Sector Under Broad Selling Pressure

Market Focus
·
Jun 22

Innovent doses first patient in Phase 3 China trial of IBI3003 tri-specific antibody for multiple myeloma

Reuters
·
Jun 22

Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of Ibi3003(Gprc5d/Bcma/Cd3 Tri-Specific Antibody) for the Treatment of Multiple Myeloma

THOMSON REUTERS
·
Jun 22

Innovent Biologics (SEHK:1801) Stock Could Be 49% Below Fair Value After ADA Pipeline Update

Simply Wall St.
·
Jun 22

Movement Alert|Innovent Biologics Rises 3.07% in Regular Trading, Biotech Sector Rally and EULAR Conference Data Provide Dual Catalysts

Market Focus
·
Jun 18